Fine-tuning targeted therapy of CML

Abstract

In this issue of Blood,Müller and colleagues correlate clinical outcome on dasatinib with baseline BCR-ABL kinase domain mutation status, providing a framework for incorporation of BCR-ABL genotype in choosing the optimal second-line kinase inhibitor therapy in imatinib-resistant patients.1 This study should help improve outcomes by personalizing therapy based on the mutations detected.